Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin and pancreatic cancer

This article was originally published in The Tan Sheet

Executive Summary

Researchers estimate "43% of pancreatic cancer cases among nonusers of aspirin might be prevented by aspirin use," according to prospective study appearing in Aug. 7 Journal of the National Cancer Institute. Kristen Anderson, PhD, University of Minnesota, et al., followed 28,283 post-menopausal women from the Iowa Women's Health Study between 1992-1999, identifying 80 cases of pancreatic cancer. Researchers observed "a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week," finding a 61% reduced risk when aspirin was used at least six times per week. Data "indicate that aspirin might be chemopreventive for pancreatic cancer," Anderson et al. say, although they recommend further studies "with detailed assessments of dose, duration and drug type used"...

You may also be interested in...



India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?

Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.

QUOTED. 5 March 2021. Dedi Gilad.

Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.

Orphan Drug Spending: Could Sequence Of Indications Offer Pricing Policy Solution?

Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel